Moser Carlos L, Martin-Baranera Montserrat, Garat Magela, de Miguel Pedro Víctor, Rubio Marc
Ophthalmology Department, Hospital General de L'Hospitalet, Consorci Sanitari Integral, L'Hospitalet de Llobregat, Barcelona, Spain.
J Cataract Refract Surg. 2004 Nov;30(11):2359-65. doi: 10.1016/j.jcrs.2004.05.004.
To compare the protective effect of Healon5 (sodium hyaluronate 2.3%) and Amvisc Plus (sodium hyaluronate 1.6%) against corneal edema and their association with postoperative intraocular pressure (IOP) spikes in patients having phacoemulsification and intraocular lens (IOL) implantation.
Ophthalmology department of a general hospital.
One hundred forty patients were randomly assigned to have surgery with Healon5 (n = 70) or Amvisc Plus (n = 70). One eye of each patient was analyzed. Data collected preoperatively included best corrected visual acuity (BCVA) and IOP. Central ultrasonic pachymetry was performed in all patients. The same ophthalmologist performed all surgeries. The IOP and central corneal thickness (CCT) were measured 1 and 4 days and 1 month after surgery. The BCVA was also assessed at 1 month.
There were no significant preoperative differences between the Healon5 and Amvisc Plus groups in sex, age, ocular pathology, BCVA, IOP, or CCT. Intraoperative variables were similar between groups, but it took significantly longer to remove the Healon5. Postoperatively, there were no differences between groups in the evolution of CCT or of IOP. Intraocular pressure spikes over 30 mm Hg were detected at 1 day in 7 patients in the Healon5 group and 2 patients in the Amvisc Plus group (10.0% versus 2.9%; P = .165).
Both OVDs were beneficial in a wide range of cataract patients. However, the results suggest a tendency toward a higher complication rate with Healon5.
比较Healon5（2.3%透明质酸钠）和Amvisc Plus（1.6%透明质酸钠）对白内障超声乳化吸除联合人工晶状体植入术患者角膜水肿的保护作用及其与术后眼压升高的关系。
一家综合医院的眼科。
140例患者被随机分配接受Healon5（n = 70）或Amvisc Plus（n = 70）手术。分析每位患者的一只眼。术前收集的数据包括最佳矫正视力（BCVA）和眼压。所有患者均进行中央超声角膜测厚。所有手术均由同一位眼科医生进行。术后1天、4天和1个月测量眼压和中央角膜厚度（CCT）。术后1个月也评估BCVA。
Healon5组和Amvisc Plus组在性别、年龄、眼部病理、BCVA、眼压或CCT方面术前无显著差异。两组术中变量相似，但Healon5的清除时间明显更长。术后，两组在CCT或眼压变化方面无差异。Healon5组7例患者和Amvisc Plus组2例患者在术后1天检测到眼压超过30 mmHg（10.0%对2.9%；P = 0.165）。
两种眼前节粘弹剂对广泛的白内障患者均有益。然而，结果表明Healon5的并发症发生率有升高趋势。
